Receiver operating characteristic area under the curve (ROCAUC) with 95% confidence interval for the clinical model and the omics separately or in combination with the clinical model in the IMI DIRECT combined cohort.
| Title: | Receiver operating characteristic area under the curve (ROCAUC) with 95% confidence interval for the clinical model and the omics separately or in combination with the clinical model in the IMI DIRECT combined cohort. |
|---|---|
| Authors: | Naeimeh Atabaki-Pasdar; Mattias Ohlsson; Ana Viñuela; Francesca Frau; Hugo Pomares-Millan; Mark Haid; Angus G. Jones; E. Louise Thomas; Robert W. Koivula; Azra Kurbasic; Pascal M. Mutie; Hugo Fitipaldi; Juan Fernandez; Adem Y. Dawed; Giuseppe N. Giordano; Ian M. Forgie; Timothy J. McDonald; Femke Rutters; Henna Cederberg; Elizaveta Chabanova; Matilda Dale; Federico De Masi; Cecilia Engel Thomas; Kristine H. Allin; Tue H. Hansen; Alison Heggie; Mun-Gwan Hong; Petra J. M. Elders; Gwen Kennedy; Tarja Kokkola; Helle Krogh Pedersen; Anubha Mahajan; Donna McEvoy; Francois Pattou; Violeta Raverdy; Ragna S. Häussler; Sapna Sharma; Henrik S. Thomsen; Jagadish Vangipurapu; Henrik Vestergaard; Leen M. ‘t Hart; Jerzy Adamski; Petra B. Musholt; Soren Brage; Søren Brunak; Emmanouil Dermitzakis; Gary Frost; Torben Hansen; Markku Laakso; Oluf Pedersen; Martin Ridderstråle; Hartmut Ruetten; Andrew T. Hattersley; Mark Walker; Joline W. J. Beulens; Andrea Mari; Jochen M. Schwenk; Ramneek Gupta; Mark I. McCarthy; Ewan R. Pearson; Jimmy D. Bell; Imre Pavo; Paul W. Franks |
| Publication Year: | 2020 |
| Subject Terms: | Biochemistry; Medicine; Genetics; Biotechnology; Biological Sciences not elsewhere classified; Chemical Sciences not elsewhere classified; omics data; combination; IMI DIRECT cohorts Background Non-alcoholic; Trial registration ClinicalTrials.gov NCT 03814915; LASSO; noninvasive NAFLD prediction tools; type 2 diabetes; omics variables; liver disease; T 2D; CI; IMI DIRECT prediction models; ROCAUC; stat; demo |
| Description: | Clinical (C), model 4, with the 22 selected clinical variables. Genetic (G), model 5, with 23 SNPs. C+G, model 6, with clinical plus genetic variables. Transcriptomic (T), model 7, with 93 protein-coding genes. T+C, model 8, with transcriptomic plus clinical variables. Proteomic (P), model 9, with 22 proteins from exploratory proteomics. P+C, model 10, with proteomic plus clinical variables. Metabolomic (M), model 11, with 25 metabolites from targeted metabolomics. M+C, model 12, with metabolomic plus clinical variables. G+T+M+P, model 13, with all omics together. C+G+T+M+P, model 14, with all the omics combined with the clinical model. |
| Document Type: | still image |
| Language: | unknown |
| Relation: | https://doi.org/10.1371/journal.pmed.1003149.g005 |
| DOI: | 10.1371/journal.pmed.1003149.g005 |
| Availability: | https://doi.org/10.1371/journal.pmed.1003149.g005 |
| Rights: | undefined |
| Accession Number: | edsbas.DED3FA4F |
| Database: | BASE |